The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...
Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...
In adults with cystic fibrosis, gastrointestinal symptoms initially improve with ETI but most do not consistently improve with longer-term use.
Vertex Pharmaceuticals (NASDAQ:VRTX) received an upgrade from Canaccord Genuity after the cystic fibrosis drugmaker exceeded consensus revenue estimates but missed on earnings with its Q4 2024 ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback